搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
23 小时
Trump vs Harris—who's on Big Pharma's side?
US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have ...
The Pharma Letter
23 小时
How biopharma companies can make the best choices
Leslie Orne, president and CEO of Trinity Life Sciences, emphasizes the importance of corporate efficiency in the highly ...
The Pharma Letter
23 小时
Takeda‘s Fruzaqla wins UK approval for CRC
The UK’s MHRA has approved Takeda’s Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC) in adults who have not ...
The Pharma Letter
1 天
Novo Nordisk’s obesity newcomer monlunabant heads into Phase IIb
Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.
The Pharma Letter
1 天
Achilles Thera shifts focus to new cancer treatment avenues
Achilles Therapeutics has announced it will discontinue its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T ...
The Pharma Letter
1 天
FDA approves first Niemann-Pick disease, type C treatment
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of ...
The Pharma Letter
1 天
Latest batch of EMA’s human medicines committee recommendations
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
The Pharma Letter
1 天
Wegovy label should be extended, CHMP recommends
The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...
The Pharma Letter
1 天
Phase III win for tolebrutinib in progressive multiple sclerosis
Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...
The Pharma Letter
1 天
BioXcel announces new priorities
BioXcel Therapeutics has announced a clinical reprioritization, focusing on late-stage development of its agitation treatment ...
The Pharma Letter
1 天
$268 million BARDA deal for Basilea
Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...
The Pharma Letter
1 天
Edgewise shares jump after positive heart drug data
Edgewise Therapeutics has reported positive top-line results for its HCM treatment candidate, EDG-7500, boosting shares by ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈